PR
DGX icon

Payden & Rygel’s Quest Diagnostics DGX Stock Holding History

Payden & Rygel’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7M Buy
92,740
+16,140
+21% +$3.17M 1.51% 22
2026
Q1 		$15M Sell
76,600
-16,800
-18% -$3.26M 1.16% 33
2025
Q4 		$16.2M Sell
93,400
-800
-0.8% -$146K 1.12% 32
2025
Q3 		$18M Buy
94,200
+600
+0.6% +$106K 1.49% 27
2025
Q2 		$16.8M Buy
+93,600
New +$16.3M 1.39% 31

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Payden & Rygel's DGX Position: Q2 2026 in Review

Payden & Rygel increased its Quest Diagnostics (DGX) stake by 21% in Q2 2026, buying an estimated $3.17M and bringing the position to 92,740 shares worth $19.7M. The position accounts for 1.51% of the portfolio, ranked #22.

Payden & Rygel first reported a position in DGX in Q2 2025 and has held it in 5 quarters since. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Payden & Rygel held 92,740 shares of Quest Diagnostics worth $19.7M as of Q2 2026.
  • Payden & Rygel bought 16,140 Quest Diagnostics shares in Q2 2026, an estimated $3.17M.
  • Quest Diagnostics made up 1.51% of Payden & Rygel's portfolio in Q2 2026, its #22 holding.
  • Payden & Rygel first reported a position in Quest Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Payden & Rygel's 13F filing for Q2 2026, filed 31 Jul 2026.